Navigation Links
Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
Date:12/10/2007

relations department.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb's Research and Development organization are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development of biological products and the submission of applications to market such products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the development of the product described in this release will be successful or that the clinical studies described in this release will support the filing of a Biological License Application (BLA) with the U.S. Food and Drug Administration (FDA). Furthermore, there can be no assurances that if a BLA is filed with the FDA, that it will be filed in the timeframe described in this release or that the BLA for the product described in this release will receive regulatory appro
'/>"/>

SOURCE Bristol-Myers Squibb Company; Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
2. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
3. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
4. Tickets Still Available for Detroit Uncorked;
5. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
6. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
7. Fingertip Formulary Mobile(TM) is Now Available for Physicians and Other Healthcare Providers Free on PDAs
8. New Resource for Taking Care of Aging Parents Available in Beta
9. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
10. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
11. Updated Brochure on Gynecologic Cancer Treatments Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
(Date:8/20/2014)... Aug. 20, 2014 The National Necrotizing Fasciitis Foundation ... has been successfully treated for a life threatening form ... Anibal R. Gauto , Medical Director of Inpatient Wound Care ... Center in Rancho Mirage, California . ... Dr. John Crew at Seton Hospital in ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and Markets ... of Pralmorelin" report to their offering. ... comprehensive data on Pralmorelin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
Inquire...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
Medicine Products: